Print Page  |  Close Window

Press Releases

ChromaDex to Present at the 3rd Annual NAD+ Summit
Chief Scientific Advisor of ChromaDex, Dr. Charles Brenner, Headlines Presentation “NAD+: What It Is, How We Lose It, and How To Boost It”

IRVINE, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today it will sponsor a gathering of scientific leaders at the 2018 NAD+ Summit on January 26-28, 2018 in San Diego, CA.

In collaboration with the Center for Research on Addiction and Brain Health, the NAD+ Treatment Center, and Springfield Wellness Center, ChromaDex will share its knowledge of nicotinamide riboside (NR) and nicotinamide adenine dinucleotide (NAD+) with leading scientists, doctors, innovators and thought leaders in the NAD+ community along with all other consumers and participants who are welcome to attend the summit.

ChromaDex’s Founder and CEO, Frank Jaksch, stated, “As a company at the forefront of NR and NAD+ research, we sponsor these types of meetings to enhance scientific collaboration and also provide education about the benefits of NIAGEN® NR and its proven ability to safely increase NAD+.”

ChromaDex has enabled the proliferation of NR research by developing, commercializing and supplying NIAGEN®, which has been rigorously tested for safety and has been the subject of Notifications filed with the U.S. Food and Drug Administration (FDA).

Currently, ChromaDex is providing NIAGEN® at no cost to independent investigators who are  leading nearly 130 programs in 34 different areas of health research such as brain and heart health, immunity, and inflammation. NIAGEN® is being utilized in at least 11 of the 14 human clinical trials currently listed on 

ChromaDex’s Chief Scientific Advisor and Roy J. Carver Chair and Head of Biochemistry, University of Iowa, Dr. Charles Brenner, will headline the presentation “NAD+: What It Is, How We lose It and How to Boost It.” Brenner, the world’s foremost authority on NAD+ metabolism and lead author on the first published human clinical trial of NIAGEN®, discovered the critical pathway by which NR is converted to NAD+ in humans (the NRK1 Pathway.)

In more than 45 additional publications and issued patents on NAD+, Dr. Brenner has identified previously unknown steps in NAD+ biosynthesis, has shown that NR increases sirtuin activity, has demonstrated increases in lifespan in model systems, has developed methods for quantitative NAD+ metabolomics, and has expanded research into novel therapeutic areas.

NIAGEN® is the key active ingredient in the Company’s NAD+ boosting nutraceutical, TRU NIAGEN®, which is now sold by ChromaDex direct to consumers. The company will be distributing sample bottles of TRU NIAGEN® at the summit.  For more information, visit

About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD+ and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. To learn more about ChromaDex, please visit

Forward-Looking Statements:
This release contains forward-looking statements relating to ChromaDex and ChromaDex’s business within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to ongoing studies and NR and the benefits of NIAGEN®. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. 

ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations

ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing

Primary Logo

ChromaDex Corporation